Mr. Fabio Chianelli reports

PHARMATHER ESTABLISHES PERSONALIZ3D TO COMMERCIALIZE A PERSONALIZED MEDICINE PLATFORM COMBINING TELEHEALTH AND PHARMACEUTICAL 3D PRINTING

Pharmather Holdings Ltd. has established Personaliz3D, an integrated ecosystem that will combine telehealth, pharmaceutical 3-D printing and pharmacy fulfilment to support the delivery of personalized medicines.

Personaliz3D expands Pharmather's previously announced Personaliz3D peptides initiative into a broader platform that includes additional therapeutic categories and compounded prescriptions, in which personalized doses, combinations, release profiles and dosage forms are produced through digitally controlled pharmacy workflows with built-in quality assurance and end-to-end traceability, potentially addressing patient needs and enhancing safety and confidence.

The Personaliz3D business model is designed to:

1. Connect patients with independent licensed health care providers through telehealth;
2. Personalize prescribed medicines using pharmaceutical 3-D printing technology;
3. Deliver the medicines through qualified pharmacy partners; and
4. Scale through a network of pharmacy-based pharmaceutical 3-D printing systems.

Pharmather believes this model may provide a reproducible and scalable alternative to traditional telehealth prescribing and dispensing of fixed, off-the-shelf medications, forming the foundation of a differentiated personalized medicine platform.

A significant market opportunity

Personalized medicine is shifting health care from standardized treatments toward therapies tailored to individual patient needs. Grand View Research estimates that the global personalized medicine market could grow from approximately $570-billion (U.S.) in 2024 to approximately $1.2-trillion (U.S.) by 2033.

Peptides represent a timely starting point due to growing interest among patients and health care providers across multiple therapeutic areas. In July, 2026, the U.S. Food and Drug Administration's pharmacy compounding advisory committee made favourable recommendations concerning certain BPC-157-, KPV-, TB-500-, MOTS-C-, Epitalon- and Semax-related bulk drug substances for the Section 503A bulks list.

Pharmather believes these recommendations represent a potential regulatory tailwind and support the evaluation of certain peptides as an initial opportunity for Personaliz3D.

In parallel, the company will evaluate additional therapeutic categories in which pharmaceutical 3-D printing may improve dosing flexibility, convenience or the overall patient experience.

"Personaliz3D is being designed around two synergistic business units: a telehealth platform intended to help generate demand for personalized medicines and a pharmacy-based 3-D printing network intended to satisfy that demand," said Fabio Chianelli, chief executive officer of Pharmather. "By connecting telehealth access, pharmacy-based production and digital traceability, we believe Personaliz3D can provide a differentiated and scalable model for personalized medicines."

From initial commercial footprint to a scalable distributed network

Pharmather plans to advance Personaliz3D through three stages:

1. Establish the centre of excellence

Select a qualified Section 503A pharmacy to serve as the Personaliz3D center of excellence. Subject to final arrangements, the location is expected to serve as the initial pharmacy fulfilment centre for telehealth prescriptions and to support the evaluation of pharmaceutical 3-D printing systems, product development, pharmacy workflows, demonstrations and partner training.

2. Launch the Personaliz3D telehealth platform

Introduce a controlled telehealth-enabled commercial program connecting eligible patients with independent licensed health care providers and qualified pharmacy fulfillment.

3. Scale through pharmacy system placements

Pharmather plans to evaluate and introduce a controlled commercial rollout of pharmaceutical 3-D printing system placements with qualified U.S. Section 503A pharmacy partners and compound pharmacies in Canada.

According to the American Pharmacists Association, there are about 56,000 community-based or retail pharmacies in the United States. Of these, about 7,500 are compounding pharmacies. Pharmather views this large pharmacy base as a potentially significant market for pharmaceutical 3-D printing systems and recurring services.

Personaliz3D will build upon Pharmather's existing collaboration with Craft Health and its CraftMake pharmaceutical 3-D printing system, and may evaluate additional systems to support the company's goal of enabling personalized medicine through pharmaceutical 3-D printing.

Building long-term recurring revenue channels

The Personaliz3D business model is designed to generate potential revenue from several parts of the ecosystem:

• Telehealth platform;
• 3-D printing system placements, consumables, software access, and continuing maintenance and support; and
• Product development, sales and licensing through strategic and commercial partnerships.

The telehealth and pharmacy network business units are designed to reinforce one another. The telehealth platform may help generate patient demand and prescriptions while the pharmacy network may expand access and fulfilment capacity for personalized medicines. As both demand and system adoption grow, Pharmather believes the platform could support broader and more scalable revenue opportunities.

About Personaliz3D

Personaliz3D is Pharmather's planned personalized medicine platform designed to integrate telehealth, pharmaceutical 3-D printing and qualified pharmacy fulfilment. The platform focuses on enabling patient-specific therapies, initially including peptides and other therapeutic categories where individualized doses, release profiles or dosage forms may address patient needs. It is structured around two synergistic components: a telehealth-enabled pathway that supports prescription generation by independent licensed health care providers and a pharmacy-based 3-D printing deployment model that enables scalable, on-demand production and fulfilment of personalized medicines.

Personaliz3D remains under development and has not commenced commercial operations.

About Pharmather Holdings Ltd.

Pharmather is a life science company focused on personalized medicines.

We seek Safe Harbor.